Vanda Pharmaceuticals Inc. (VNDA)
| Market Cap | 319.51M |
| Revenue (ttm) | 177.60M |
| Net Income (ttm) | -4.89M |
| Shares Out | 58.20M |
| EPS (ttm) | -0.09 |
| PE Ratio | n/a |
| Forward PE | 30.30 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 670,223 |
| Open | 5.53 |
| Previous Close | 5.58 |
| Day's Range | 5.47 - 5.69 |
| 52-Week Range | 3.30 - 6.76 |
| Beta | 0.71 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 8, 2024 |
About VNDA
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bi... [Read more]
Financial Performance
In 2023, VNDA's revenue was $192.64 million, a decrease of -24.27% compared to the previous year's $254.38 million. Earnings were $2.51 million, a decrease of -60.02%.
Financial StatementsNews
Vanda Pharmaceuticals Reports Positive Results from a Second Phase III Study of Tradipitant in Motion Sickness
• New Drug Application expected to be submitted in Q4 2024 WASHINGTON , May 15, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the results from its seco...
Vanda Pharmaceuticals Reports First Quarter 2024 Financial Results
Revenues for Q1 2024 were $47.5 million, an increase of 5% compared to Q4 2023 Cash increase of $5.9 million in Q1 2024 to $394.1 million Fanapt® approved for the acute treatment of bipolar I disorder...
Vanda Pharmaceuticals Confirms Receipt of Revised Unsolicited Takeover Proposal from Future Pak
No Shareholder Action Required at This Time WASHINGTON , May 7, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. ("Vanda" or the "Company") (Nasdaq: VNDA) today confirmed that it has received a revised...
Future Pak Increases Bid for Vanda Pharmaceuticals to Include CVRs in Addition to $7.25 to $7.75 Per Share in Cash
WIXOM, Mich.--(BUSINESS WIRE)--Future Pak LLC (“Future Pak”) confirms it increased its offer for all outstanding shares of common stock of Vanda Pharmaceuticals (“Vanda” or “the Company”) (NYSE: VNDA)...
Vanda Pharmaceuticals to Announce First Quarter 2024 Financial Results on May 8, 2024
Conference Call and Webcast to Follow WASHINGTON , April 30, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the first quarter 2024 o...
Shareholder Capital asks Vanda Pharma's board to reconsider Future Pak's offer
Investment firm Shareholder Capital sent a letter to drugmaker Vanda Pharmaceuticals' board on Thursday asking it to reconsider Future Pak's takeover offer.
Vanda Pharmaceuticals Reacts to U.S. Supreme Court's Denial of its Petition in HETLIOZ® ANDA Litigation
WASHINGTON , April 22, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the Supreme Court denied Vanda's petition for a writ of certiorari in its HETLIOZ® Ab...
U.S. Supreme Court rejects Vanda Pharmaceuticals case over sleep-drug patents
The U.S. Supreme Court on Monday declined to hear a bid by Vanda Pharmaceuticals to revive patents for its sleep-disorder drug Hetlioz that were previously declared invalid in a dispute with generic d...
Butler Hall Capital urges Vanda to engage in sales discussions
Hedge fund manager Butler Hall Capital said on Friday it is urging Vanda Pharmaceuticals to form an independent special committee to engage with Future Pak over its takeover offer and run a full sales...
Vanda Pharmaceuticals Adopts Limited Duration Stockholder Rights Plan
WASHINGTON , April 17, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. ("Vanda" or the "Company") (Nasdaq: VNDA) today announced that its Board of Directors (the "Board") has adopted a limited duratio...
Vanda Pharmaceuticals rejects takeover proposal from Future Pak
Vanda Pharmaceuticals Inc on Wednesday said it is rejecting a takeover proposal from Future Pak, a privately-held contract manufacturer and packager of pharmaceuticals, as it significantly undervalues...
Vanda Pharmaceuticals Confirms Rejection of Unsolicited Takeover Proposals from Future Pak
Board Determined Unsolicited Takeover Proposals Significantly Undervalue the Company No Shareholder Action Required at This Time WASHINGTON , April 17, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. ...
Future Pak Confirms Proposal to Acquire Vanda Pharmaceuticals for $7.25 to $7.75 Per Share in Cash
WIXOM, Mich.--(BUSINESS WIRE)--Future Pak LLC (“Future Pak”) today announced that it has submitted three proposals since February to acquire all of the outstanding shares of common stock of Vanda Phar...
Vanda Pharmaceuticals shares jump 30% after FDA approval of Fanapt for bipolar I disorder
Shares of Vanda Pharmaceuticals VNDA, -5.10% jumped 33% to $5.23 in post-market trading after the company said the Food and Drug Administration approved Fanapt to treat manic or mixed episodes associa...
US FDA approves Vanda's drug for bipolar disorder
The U.S. FDA approved Vanda Pharmaceuticals' drug to treat manic and mixed episodes associated with a type of bipolar disorder, the company said on Tuesday, marking the second approval for the treatme...
Vanda Pharmaceuticals' Fanapt® (iloperidone) Receives U.S. FDA Approval for the Acute Treatment of Bipolar I Disorder
Fanapt® Treatment is Now Available to Adult Patients for the Acute Treatment of Manic or Mixed Episodes Associated with Bipolar I Disorder Approval Represents Significant Novel Indication for Vanda's ...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Vanda Pharmaceutical Inc. - VNDA
NEW YORK , March 27, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Vanda Pharmaceutical Inc. ("Vanda" or the "Company") (NASDAQ: VNDA). Such investors are advise...
Vanda Pharmaceuticals Announces FDA Update for supplemental NDA for HETLIOZ® in the Treatment of Insomnia
WASHINGTON , March 6, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that on March 4, 2024, it received a Complete Response Letter (CRL) from the U.S. Food and ...
Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
Full year 2023 revenues were $192.6 million PONVORY® acquisition completed in Q4 2023 and transition ongoing 3 FDA PDUFA target action dates in 2024 Ended 2023 with approximately $388 million in cash ...
Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results on February 7, 2024
Conference Call and Webcast to Follow WASHINGTON , Jan. 31, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the fourth quarter and fu...
Vanda Pharmaceuticals Receives FDA Approval to Proceed with Investigational New Drug VTR-297 a Topical Antifungal Candidate for the Treatment of Onychomycosis
WASHINGTON , Jan. 31, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug ...
Court Orders FDA to Resolve Vanda Pharmaceuticals' Jet Lag Hearing Request by March 5, 2024
WASHINGTON , Jan. 30, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the United States District Court for the District of Columbia granted Vanda's motion f...
Vanda Pharmaceuticals Announces a U.S. Patent Allowance for PONVORY® (ponesimod) in the U.S.
WASHINGTON , Jan. 25, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Patent and Trademark Office has issued a notice of allowance for its PONVORY®...
Vanda Pharmaceuticals announces the publication of an article on "The Efficacy of Tradipitant in Patients with Diabetic and Idiopathic Gastroparesis in Phase III Randomized Placebo-Controlled Clinical Trial" in the Clinical Gastroenterology and Hepatology Journal
WASHINGTON , Jan. 25, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the publication of an article titled "The Efficacy of Tradipitant in Patients with Diabetic...
Vanda Pharmaceuticals Receives FDA Approval to Proceed with Investigational New Drug VCA-894A, a Novel Antisense Oligonucleotide Candidate for the Treatment of Charcot-Marie-Tooth Disease, Type 2S
WASHINGTON , Jan. 23, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug ...